Phosphorex at the 44th Controlled Release Society Annual Meeting and Exposition in Boston
Hopkinton, Mass., July 14, 2017 — Phosphorex, Inc., a leading drug delivery company, today announced its participation in the upcoming Annual Meeting and Exposition of the Controlled Release Society, to be held at the Boston Convention Center, Boston, Massachusetts, on July 16 – 19, 2017.
At the conference, Phosphorex will showcase its drug delivery platforms and development solutions. This includes its microsphere capabilities for sustained drug release and nanoparticle technology which enables targeted delivery for oncology, immunology, and other therapeutic applications.
Visit us at exhibit #619 at the Controlled Release Society Annual Meeting.
Julia Rashba-Step, Vice President of R&D and Alliance Management, and Theresa Logan, Associate Director of Project Management will be available throughout the exhibition to discuss the company’s full range of capabilities. This includes its integrated solution to support all aspects of product development encompassing prototype fabrication, formulation and process optimization, analytical development, scale up, good laboratory practice (GLP), and good manufacturing practice (GMP).
For more information on the event and to arrange a meeting with any of the attending Phosphorex representatives, please contact Kyle Caron – email@example.com.
Phosphorex is a worldwide provider of drug delivery technologies and solutions. By harnessing the potential of microspheres and nanoparticles for drug delivery, Phosphorex offers tailored solutions and enabling technologies to optimize a drug’s release rate, targeting ability, and bioavailability, thereby achieving desired therapeutic effects while reducing adverse clinical outcomes. Phosphorex partners with pharmaceutical companies by supporting all phases of their development from proof of concept to clinical studies.
For more information, visit www.phosphorex.com
Microspheres, Nanoparticles and Drug Delivery.